News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
224,586 Results
Type
Article (5119)
Company Profile (18)
Press Release (219449)
Section
Business (82429)
Career Advice (462)
Deals (15067)
Drug Delivery (8)
Drug Development (19401)
Employer Resources (30)
FDA (3696)
Job Trends (3911)
News (120664)
Policy (7548)
Tag
Academia (311)
Alliances (14809)
Alzheimer's disease (247)
Approvals (3705)
Artificial intelligence (32)
Bankruptcy (96)
Best Places to Work (2873)
Breast cancer (42)
Cancer (367)
Career advice (392)
Cell therapy (88)
Clinical research (16156)
Collaboration (134)
Compensation (125)
COVID-19 (304)
C-suite (73)
Data (412)
Diabetes (32)
Diagnostics (2027)
Earnings (40309)
Employer resources (31)
Events (37568)
Executive appointments (248)
FDA (3889)
Funding (156)
Gene therapy (45)
GLP-1 (101)
Government (410)
Healthcare (5065)
Infectious disease (316)
Interviews (53)
IPO (7812)
Job creations (1123)
Job search strategy (361)
Layoffs (101)
Legal (2330)
Lung cancer (40)
Manufacturing (41)
Medical device (3853)
Medtech (3854)
Mergers & acquisitions (7413)
Metabolic disorders (100)
Neuroscience (326)
NextGen: Class of 2025 (1687)
Non-profit (743)
Northern California (748)
Obesity (47)
Opinion (30)
People (24509)
Phase I (4841)
Phase II (7049)
Phase III (5559)
Pipeline (354)
Postmarket research (633)
Preclinical (1880)
Press Release (66)
Prostate cancer (24)
Radiopharmaceuticals (105)
Rare diseases (66)
Real estate (1873)
Regulatory (5103)
Research institute (309)
Resumes & cover letters (68)
Southern California (551)
Startups (1016)
United States (5762)
Vaccines (29)
Date
Last 7 days (173)
Last 30 days (716)
Last 365 days (10732)
2025 (1305)
2024 (11125)
2023 (13267)
2022 (18764)
2021 (19805)
2020 (18325)
2019 (13274)
2018 (10252)
2017 (10044)
2016 (9198)
2015 (12171)
2014 (9640)
2013 (7753)
2012 (8383)
2011 (8853)
2010 (8682)
Location
Africa (183)
Arizona (52)
Asia (11420)
Australia (1593)
California (1553)
Canada (610)
China (48)
Colorado (66)
Connecticut (81)
Europe (24403)
Florida (204)
Georgia (28)
Illinois (103)
Indiana (50)
Japan (54)
Maine (37)
Maryland (181)
Massachusetts (1266)
Michigan (80)
Minnesota (121)
New Jersey (458)
New York (394)
North Carolina (283)
Northern California (748)
Ohio (47)
Pennsylvania (287)
South America (275)
Southern California (551)
Tennessee (25)
Texas (180)
Utah (48)
Virginia (31)
Washington State (140)
224,586 Results for "neurogen corporation".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Gene therapy
Neurogene Details Gene Therapy Complication, Sending Shares Plummeting Again
Neurogene’s shares fell by 36% as the market opened Monday morning following news that a patient experienced systemic hyperinflammatory syndrome in a Phase I/II clinical trial of Rett syndrome gene therapy NGN-401.
November 18, 2024
·
2 min read
·
Annalee Armstrong
Pipeline
Neurogene Drops Batten Gene Therapy Program
After failing to receive the RMAT designation from the FDA for its early-stage Batten disease gene therapy, Neurogene tells investors that it’s evaluating options for the program.
November 19, 2024
·
2 min read
·
Kate Goodwin
Gene therapy
Patient Death in Rett Syndrome Trial Forces Neurogene to Drop High-Dose Arm
Despite the death, the FDA has allowed Neurogene to forge ahead with the Phase I/II Rett syndrome trial, but using only the lower 1E15 vg dose of its investigational gene therapy NGN-401.
November 22, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Neurogene Announces Addition to Russell 3000® Index
Neurogene Inc. today announced that Neurogene will be added to the Russell 3000 ® Index, effective at the open of U.S. equity markets today, Monday, July 1, 2024.
July 1, 2024
·
5 min read
Pharm Country
Neurogene to Participate in Upcoming Conferences
Neurogene Inc. today announced that Company management will participate in the following conferences.
June 5, 2024
·
2 min read
Podcast
RFK Jr.’s HHS Nomination, Biogen’s Lupus Win and Leqembi Struggles, Neurogene’s Rough Month, More
Trump fingers Robert F. Kennedy Jr. to lead the HHS, lupus and ATTR-CM dominate headlines this week, bluebird bio has a cash gap to leap and RegenxBio eyes Sarepta in Duchenne muscular dystrophy.
November 20, 2024
·
1 min read
·
Heather McKenzie
Business
Neurogene Reports First Quarter 2024 Financial Results and Highlights Recent Updates
Neurogene Inc., a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, announced first quarter 2024 financial results and highlighted recent corporate updates.
May 10, 2024
·
10 min read
Press Releases
Neurogene Announces Oversubscribed $200 Million Private Placement
November 5, 2024
·
6 min read
Press Releases
Neurogen Biomarking Announces Global Agreement with Quanterix for Use of Blood Biomarker Assay in its Patient-Initiated Blood Test to Support Early Detection of Dementia and Mild Cognitive Impairment Due to Alzheimer’s Disease
February 19, 2025
·
4 min read
Pharm Country
Neurogene to Participate in Upcoming Investor Conferences
Neurogene Inc. today announced that Company management will participate in the following investor conferences.
February 29, 2024
·
1 min read
1 of 22,459
Next
